Immuneering Stock - weekly review in a volatile biotech market

Edited by ad hoc news Long-Term & Business-Model Desk. Verified prior to publication on 06/20/2026, 17:43 CET. Details in the imprint.

Immuneering (US45255L1089) is ending this week quietly on Nasdaq, with the stock holding near recent levels and no new filings or press releases published. Trading data and sector moves therefore provide the main signals for investors watching the name.

How Immuneering traded this week

Immuneering shares last closed at $4.41 on Nasdaq on 06/18/2026, unchanged on the day on regular volume, according to MarketBeat data. MarketBeat quote page for IMRX

The stock’s 52-week range runs from $2.29 to $10.08, underlining the high volatility that is typical for small-cap biotechnology names. MarketBeat overview of Immuneering

Weekly review and sector context

With a recent market capitalization of roughly $285 million, Immuneering sits firmly in the micro- to small-cap bracket of the biotech universe. TradingKey technical snapshot for IMRX

TradingKey data show the stock near technical support around $3.22 and resistance near $6.25, placing the current price in the middle of this trading band and highlighting a range-bound pattern in recent months. TradingKey support and resistance levels

The business behind the stock

Immuneering is a clinical-stage biopharmaceutical company that uses its proprietary RABIT platform to design small-molecule drug candidates, with a focus on oncology and other serious diseases, according to its corporate description. MarketBeat company overview

Where the stock trades today

The shares of Immuneering (US45255L1089) trade on Nasdaq at $4.41 as of the close on 06/18/2026, 16:00 ET.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.